Donor- and patient-derived interleukin 6 knockdown CD19-targeted chimeric antigen receptor T cells exhibit similar efficacy and safety in treating relapsed B-cell acute lymphoblastic leukemia patients after allogeneic hematopoietic stem cell transplantation.

Advancing acute myeloid leukemia immunotherapy: transcriptomic profiling-guided donor selection combined with an innovative natural killer cell expansion protocol.

Improved lentivector-modified hematopoietic stem cell transplantation in the Townes mouse model of sickle cell disease.

Long-term stability of autologous peripheral blood stem cell products stored for up to 30 years.

Development of a proficiency testing platform for advanced therapies medicinal products (ATMPs).

A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancer.

Donor- and patient-derived interleukin 6 knockdown CD19-targeted chimeric antigen receptor T cells exhibit similar efficacy and safety in treating relapsed B-cell acute lymphoblastic leukemia patients after allogeneic hematopoietic stem cell transplantation.

Advancing acute myeloid leukemia immunotherapy: transcriptomic profiling-guided donor selection combined with an innovative natural killer cell expansion protocol.

Improved lentivector-modified hematopoietic stem cell transplantation in the Townes mouse model of sickle cell disease.

Long-term stability of autologous peripheral blood stem cell products stored for up to 30 years.

Development of a proficiency testing platform for advanced therapies medicinal products (ATMPs).

A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancer.